Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors-Reference-Cited by-同舟云学术

Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors

Published:2023-03-09 Issue:10 Volume:388 Page:898-912
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Gounder Mrinal¹,Ratan Ravin¹,Alcindor Thierry¹,Schöffski Patrick¹,van der Graaf Winette T.¹,Wilky Breelyn A.¹,Riedel Richard F.¹,Lim Allison¹,Smith L. Mary¹,Moody Stephanie¹,Attia Steven¹,Chawla Sant¹,D’Amato Gina¹,Federman Noah¹,Merriam Priscilla¹,Van Tine Brian A.¹,Vincenzi Bruno¹,Benson Charlotte¹,Bui Nam Quoc¹,Chugh Rashmi¹,Tinoco Gabriel¹,Charlson John¹,Dileo Palma¹,Hartner Lee¹,Lapeire Lore¹,Mazzeo Filomena¹,Palmerini Emanuela¹^ORCID,Reichardt Peter¹,Stacchiotti Silvia¹,Bailey Howard H.¹,Burgess Melissa A.¹,Cote Gregory M.¹,Davis Lara E.¹,Deshpande Hari¹,Gelderblom Hans¹,Grignani Giovanni¹,Loggers Elizabeth¹,Philip Tony¹,Pressey Joseph G.¹^ORCID,Kummar Shivaani¹,Kasper Bernd¹

Affiliation:

1. From Sarcoma Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York (M.G.), and Northwell Health Cancer Institute, New Hyde Park (T.P.) — all in New York; the Department of Sarcoma Medical Oncology, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston (R.R.); the Department of Oncology, McGill University, Montreal (T.A.); the Department of General Medical Oncology, University Hospitals Leuven, KU...

Funder

SpringWorks Therapeutics Inc.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2210140

Reference39 articles.

1. Adult desmoid tumors: biology, management and ongoing trials

2. Prospective development of a patient‐reported outcomes instrument for desmoid tumors or aggressive fibromatosis

3. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)